Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SVV-001 + Nivolumab + Ipilimumab in Advanced Neuroendocrine Tumors
NCT06889493Phase 1Recruiting
- Start
- May 2025
- Primary completion
- Jun 2030
- Modality
- Oncolytic Viruses
- Countries
- 1
01
Overview
Phase 1, open-label trial of Seneca Valley Virus in neuroendocrine carcinoma (NEC) and Neuroendocrine Neoplasm (NEN) (3 arms). Primary endpoints: Maximum Tolerated Dose / Recommended Phase 2 Dose at 12 months, Number of Participants Experiencing Dose Limiting Toxicities at 12 months and 2 more. Started May 2025; status: recruiting.
02
Drugs
Seneca Valley Virus
03
Conditions
neuroendocrine carcinoma (NEC)Neuroendocrine Neoplasm (NEN)
Beyond the preview
Go deeper on NCT06889493.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06889493.